Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

NCT02036476 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Lack of accrual.

Conditions

Merkel Cell Carcinoma
Skin Cancer

Interventions

DRUG: Cabozantinib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]